Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kureha Of Japan Signs Development Agreement With LG Lifescience Indian Subsidiary

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Japanese chemical company Kureha Feb. 13 signed an agreement with Indian subsidiary of South Korean pharmaceutical company LG Lifescience. According to the agreement, LG Lifescience obtained exclusive rights to develop and market Kureha's proprietary oral absorbent chronic renal failure treatment Kremezin (AST-120) in India. The company plans a market launch in 2012. Currently available for therapeutic use in Japan, Taiwan and Korea, AST-120 is estimated to expand in other Asian countries as well as in the U.S. and Europe. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070799

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel